Screening

ZERO – The End of Prostate Cancer and Bayer Band Together with Twisted Sister’s Jay Jay French to Raise Awareness about Prostate Cancer Screening and Treatment

Retrieved on: 
Thursday, June 17, 2021
MEN, Research, General Health, Pharmaceutical, Oncology, Consumer, Other Education, Education, Clinical trials, Science, Biotechnology, Health, Other Science, Prostate cancer, Anatomy, Medicine, Clinical medicine, Prostate, Cancer, Screening, ZERO—The End of Prostate Cancer, National Prostate Health Month, the National Prostate Cancer Education Campaign, Prostate Cancer, Oncology at Bayer, Bayer, ZERO – The End of Prostate Cancer, THE NATIONAL PROSTATE CANCER EDUCATION CAMPAIGN, PROSTATE CANCER, ONCOLOGY AT BAYER, BAYER, ZERO – THE END OF PROSTATE CANCER

Understanding family history and other risk factors is an important step in knowing when to begin screening for prostate cancer.

Key Points: 
  • Understanding family history and other risk factors is an important step in knowing when to begin screening for prostate cancer.
  • Were Not Gonna Take It is a national education campaign to raise awareness about the importance of screening and early detection of prostate cancer.
  • With support from Bayer, ZERO is proud to partner with Jay Jay French guitarist, manager, record producer and founding member of the heavy metal band Twisted Sister.
  • ZERO The End of Prostate Cancer is the leading national nonprofit with the mission to end prostate cancer.

Clearside Biomedical Announces Positive Safety Results from Cohort 1 of OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD

Retrieved on: 
Tuesday, June 15, 2021
Medicine, Medical terminology, Prevention, Screening, Medical imaging, Health sciences

The OASIS Safety Monitoring Committee has reviewed the data and the trial will advance to Cohort 2.

Key Points: 
  • The OASIS Safety Monitoring Committee has reviewed the data and the trial will advance to Cohort 2.
  • All enrolled patients underwent diagnostic imaging at screening, followed by masked reading center confirmation of persistent active disease.
  • CLS-AX was well-tolerated and these initial results in this heavily treatment-experienced group of wet AMD patients are promising.
  • These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements.

The 'New Normal' for Employees; Going to Work Will Feel Like Going Through Airport Security Screening in This Post-Pandemic World

Retrieved on: 
Monday, June 14, 2021
Medical terminology, Prevention, Screening, Medicine, Application software, Health sciences, Mobile applications, Privacy

The MyLobbyHealth Screening App will reduce the friction andthe time-consuming aspects of the screening process.

Key Points: 
  • The MyLobbyHealth Screening App will reduce the friction andthe time-consuming aspects of the screening process.
  • COVID-19 Health Screening App called MyLobby (parent company MyMedia Inc), provides a safe and secure check-in process through digitization and automation.
  • In addition, as workplaces finally reopen, COVID-19 employee screening apps will diminish bottlenecking by 75% related to manual screenings.
  • The company's COVID-19 Health Screening App has continually met organizational needs related to risk and incident management.

GO2 Foundation for Lung Cancer Expands Early Detection Efforts to Include Incidental Pulmonary Nodules (IPN) to Save More Lives

Retrieved on: 
Thursday, June 10, 2021
Medicine, Medical tests, Medical terminology, Lung cancer, Screening, Cancer, Health

SAN CARLOS, Calif. and WASHINGTON, June 10, 2021 /PRNewswire/ --To help diagnose early-stage lung cancer when it is more treatable and even curable, GO2 Foundation for Lung Cancer (GO2 Foundation) is expanding its early detection efforts to include incidental pulmonary nodule (IPN) management.

Key Points: 
  • SAN CARLOS, Calif. and WASHINGTON, June 10, 2021 /PRNewswire/ --To help diagnose early-stage lung cancer when it is more treatable and even curable, GO2 Foundation for Lung Cancer (GO2 Foundation) is expanding its early detection efforts to include incidental pulmonary nodule (IPN) management.
  • GO2 Foundation is prioritizing this work to identify and track suspicious nodules and malignancies alongside existing screening efforts, further advancing early detection for even more people.
  • "GO2 Foundation's new IPN initiative will give health care providers additional tools to diagnose lung cancer early, when it's more treatable and even curable."
  • The goal is the early detection of a lung cancer whether identified though screening or a robust IPN program."

BioMark Receives $825K Grant to Develop Its Liquid Biopsy Assay for Lung Cancer Screening

Retrieved on: 
Tuesday, June 1, 2021
Medicine, Clinical medicine, Cancer screening, Medical tests, Biopsy, Interventional radiology, Lung cancer, Liquid biopsy, Lung cancer screening, Cancer, Screening

Vancouver, British Columbia--(Newsfile Corp. - June 1, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") is pleased to announce today that its wholly-owned subsidiary BioMark Diagnostic Solutions Inc. ("BDS") received funding to develop an early-stage lung cancer screening assay using BioMark's proprietary liquid biopsy platform.

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - June 1, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") is pleased to announce today that its wholly-owned subsidiary BioMark Diagnostic Solutions Inc. ("BDS") received funding to develop an early-stage lung cancer screening assay using BioMark's proprietary liquid biopsy platform.
  • This initiative entitled "A Pan Canadian initiative for the development of a liquid biopsy assay for lung cancer screening" is being led by Dr. Philippe Joubert and a team of leading clinicians, academic researchers, and data scientists.
  • The overarching goal is to develop a low-cost, high-throughput test that will make early-stage lung cancer screening feasible and affordable for at-risk population.
  • BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor, and assess treatment for cancer early and cost-effectively.

Global Drug Screening Market Trends, Forecast, and Competitive Analysis Report 2021: Analytical Instruments, Rapid Testing Devices, & Drug Screening Services - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 1, 2021
Medical Supplies, Health, Articles, Doping in sport, Drug control law, Drug test, Tests, New product development, Screening, Human activities, Academic disciplines

The study includes the drug screening market size and forecast for the global drug screening market through 2024, segmented by product and service, sample type, end user, and region.

Key Points: 
  • The study includes the drug screening market size and forecast for the global drug screening market through 2024, segmented by product and service, sample type, end user, and region.
  • Some of the features of Global Drug Screening Market 2019-2024: Trends, Forecast, and Opportunity Analysis include:
    Market size estimates: Global drug screening market size estimation in terms of value ($M) shipment.
  • Growth opportunities: Analysis on growth opportunities in different applications and regions for drug screening in the global drug screening market.
  • Strategic analysis: This includes M&A, new product development, and competitive landscape for, drug screening in the global drug screening market.

Oncotech develops AI-powered real-time mobile cancer screening and detection system

Retrieved on: 
Thursday, May 27, 2021
Medicine, Health, Clinical medicine, Hereditary cancers, Histopathology, Prostate cancer, Breast cancer, Cancer, Oncology, Treatment of cancer, Screening, War on Cancer

Developed by Oncotech Nordic AB , Ophtascan is a mobile in-real-time detection system of pre-cancerous and all four levels of cancer conditions and targeted oncological diseases in the human body.

Key Points: 
  • Developed by Oncotech Nordic AB , Ophtascan is a mobile in-real-time detection system of pre-cancerous and all four levels of cancer conditions and targeted oncological diseases in the human body.
  • The process is quick, on demand, cost effective - and does not overload the public health care diagnostic system unnecessarily, hence eliminating patient cancer screening waiting lists.
  • "Conditions currently clinically validated and screened include lung cancer, liver cancer, breast cancer, uterine cancer, and prostate cancer."
  • The Therapeutic R&D and focus is on Diagnostics (mobile in-time cancer screening technology) and cancer treatment Therapies (breast, uterus, lung, prostate, pancreas, liver and neuroblastoma).

Oncotech develops AI-powered real-time mobile cancer screening and detection system

Retrieved on: 
Thursday, May 27, 2021
Medicine, Health, Clinical medicine, Hereditary cancers, Histopathology, Prostate cancer, Breast cancer, Cancer, Oncology, Treatment of cancer, Screening, War on Cancer

Developed by Oncotech Nordic AB , Ophtascan is a mobile in-real-time detection system of pre-cancerous and all four levels of cancer conditions and targeted oncological diseases in the human body.

Key Points: 
  • Developed by Oncotech Nordic AB , Ophtascan is a mobile in-real-time detection system of pre-cancerous and all four levels of cancer conditions and targeted oncological diseases in the human body.
  • The process is quick, on demand, cost effective - and does not overload the public health care diagnostic system unnecessarily, hence eliminating patient cancer screening waiting lists.
  • "Conditions currently clinically validated and screened include lung cancer, liver cancer, breast cancer, uterine cancer, and prostate cancer."
  • The Therapeutic R&D and focus is on Diagnostics (mobile in-time cancer screening technology) and cancer treatment Therapies (breast, uterus, lung, prostate, pancreas, liver and neuroblastoma).

Insights on the Mobile Cancer Screening Devices Global Market to 2029 - Key Drivers, Challenges and Opportunities - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 25, 2021
Health, Oncology, Medical devices, Medical terminology, Prevention, Screening, Oncology

The mobile cancer screening devices market is expected to highlighting positive growth at a compounded annual growth rate (CAGR) of 5.6% during the forecast period from 2021 to 2029.

Key Points: 
  • The mobile cancer screening devices market is expected to highlighting positive growth at a compounded annual growth rate (CAGR) of 5.6% during the forecast period from 2021 to 2029.
  • The mobile cancer screening devices are well equipped with efficient ergonomic features and are less expensive in comparison to conventional screening devices.
  • Rising prevalence of cancer worldwide and increasing demand for portable screening devices among oncologist consolidates the market growth for mobile cancer screening devices.
  • North America is responsible for 34.5% market share and is the leading regional segment for global mobile screening devices market.

Geneoscopy Announces Publication of Peer-Reviewed Article Highlighting Effective Noninvasive Screening Test for Colorectal Cancer Prevention

Retrieved on: 
Tuesday, May 25, 2021
General Health, Medical devices, Other Health, Health, Oncology, Medicine, Clinical medicine, Health, Colorectal cancer, Cancer screening, Screening, Cancer

Geneoscopy Inc. today announced publication of the peer-reviewed article, Multitarget Stool RNA Test for Noninvasive Detection of Colorectal Neoplasias in a Multicenter, Prospective, and Retrospective Cohort, which presents the results of its multifactor RNA-FIT test in Clinical and Translational Gastroenterology.

Key Points: 
  • Geneoscopy Inc. today announced publication of the peer-reviewed article, Multitarget Stool RNA Test for Noninvasive Detection of Colorectal Neoplasias in a Multicenter, Prospective, and Retrospective Cohort, which presents the results of its multifactor RNA-FIT test in Clinical and Translational Gastroenterology.
  • The article reports high sensitivity of the companys noninvasive, at-home diagnostic screening test to successfully detect colorectal neoplasms, including advanced adenomas, in average-risk individuals within the intended use population for colorectal cancer screening.
  • Geneoscopys lead diagnostic uses stool-derived eukaryotic RNA (seRNA) to detect colorectal cancer and precancerous adenomas.
  • The information contained in this release includes information about Geneoscopys future plans concerning its noninvasive molecular test that can detect colorectal cancer and precancerous adenomas, and as such constitute forward-looking statements.